Indications Prophylaxis of Yellow fever infection Pharmacology Live, attenuated virus stimulates active immunity to Yellow fever; conveys active immunity via stimulation of production of endogenously produced antibodies. Yellow fever vaccine is used for active immunisation against yellow fever. Each dose (usually 0.5 ml) contains at least 1000 mouse LD50 units. Dosage & Administration Primary Vaccination: Adults and Children >9 months: 0.5 mL of reconstituted vaccine administered as a single dose. Children : The vaccine must not be given to children The vaccine should be given at least 10 days before entering an endemic area since protective immunity may not be achieved until at least this time has elapsed. Elderly: The dose is the same as for adults. However, due to a higher risk of yellow fever vaccine-associated severe and potentially fatal disease in persons from 60 years of age, the vaccine should only be given when it is considered that there is a considerable and unavoidable risk of acquiring yellow fever infection. Re-Vaccination: Re-vaccination with 1 dose of 0.5 mL is recommended every 10 years in persons considered to be at risk of exposure. International Health Regulations (IHR) require re-vaccination, using the same dose as for primary vaccination, at intervals of 10 years in order to retain a valid certificate. For IM use, the recommended injection sites are the anterolateral aspect of the thigh in the infants and toddlers (6 months up to 2 years of age) and the deltoid muscle in older children and adults. * ????????? ??????? ??????? ??? ???? ????'